TRIAL DETAIL

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer

Drug:
Trial Name:
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 07/01/2011
Age of Trial (yrs) 11
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor + MEK inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
12876, 2010-024082-45
Sponsor:
Bayer
Patient Contact:
For trial location information (Phone Menu Options '3' or '4' (+)1-888-84 22937
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Copanlisib + Refametinib

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
9023 E. Desert Cove Ave.
Scottsdale
AZ
85260
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA
Breisacher Stra├če 117
Freiburg
D-79106
Germany
Rotterdam
Netherlands